Gene signature predicted risk of spreading Kidney cancer based on biospecimens evaluation results – a study review by BIOMEDICA CRO team
Among patients with Kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival, according to the results of a preclinical study.
In the current study, the researchers from Karolinska Institutet in Sweden examined samples from nine patients with Clear Cell Kidney cancer. Both tumor tissue and nearby normal kidney tissue were collected from the same patient to be able to make matched comparisons and control for inter-individual variation.
The investigation demonstrates that a genetic signature consisting of four specific genes predicts whether the tumor will spread to the skeleton and survive. Simultaneous overexpression of these genes (SAA1, SAA2, APOL1 and MET) suggests that the patient has a greater risk of developing a tumor that spreads and a poorer survival outcome.
The researchers say that the obtained data provides essential biological knowledge about the interaction between tumor cells and their microenvironment in Clear Cell Renal Cell Carcinoma.
Please find more information on the Karolinska Institutet website, article “Gene signature points to prognosis in kidney cancer”.
Prospective collection of human biospecimens for cancer research by Preclinical Contract Research Organization BIOMEDICA CRO
BIOMEDICA CRO team is proud to participate in preclinical trials since 2017. We are ready to provide all our knowledge and experience to support your current needs and provide you with various human biospecimens and associated clinical data.
Our primary area is oncology studies, such as:
• Kidney Cancer;
• Colorectal Cancer;
• Breast cancer;
• Prostate Cancer;
• Cervical cancer,
• Lung cancer, etc.
It is feasible to collect tissue samples (tumor/NAT FFPE blocks, fresh frozen tissue samples, histological slides, and lymph nodes), blood samples (plasma, serum, buffy coat, PBMC) and other biofluids, such as stool, urine, etc. from cancer subjects.
Besides oncology, we have 50+ contracted clinical sites in a broad range of disease areas – kindly click here to review.
Once you are close to conducting preclinical trials, we are ready to provide full support in line with good laboratory (GLP) and good clinical practices (GCP). Our team is ready to join new projects and contribute to scientific cooperation!
Please email us to start our collaboration: office@biomedica-cro.com / LinkedIn.
